Therapeutic possibilities of using an expectorant mucolytic agent with antioxidant properties in COVID-19 infection
et al., Russian Medical Inquiry,
Retrospective 111 patients with moderate COVID-19 pneumonia, 56 treated with NAC, showing shorter hospitalization time with treatment. NAC 1200mg daily intravenous, divided into two doses.
hospitalization time, 20.3% lower, relative time 0.80, p < 0.05, treatment 56, control 55.
Effect extraction follows pre-specified rules prioritizing more serious outcomes.
Ignatova et al., 11/10/2021, retrospective, Russia, Europe, peer-reviewed, median age 49.2, 12 authors, average treatment delay 4.6 days.